Biodegradable microcapsules containing bupivacaine/ dexamethasone produce an anesthetic duration of 7-11 days in animal models. In this investigation, we explored the effect of increasing doses (Part 1) and the effect of including dexamethasone (Part 2) on the onset, density, and duration of analgesia and anesthesia produced by bupivacaine microcapsules. Concentrations ranging from 0.3125% to 5.0% in microcapsules were compared with 0.25% aqueous bupivacaine (bilateral injection, three intercostal nerves, 2 mL per nerve) (Part 1). Part 2 compared 2.5% microcapsules with or without the inclusion of dexamethasone by unilateral blockade. Sensory block was assessed by pinprick, temperature sensation, and subjective numbness (0, not numb; 10, totally numb). Pharmacodynamic assessments and plasma drug concentrations of bupivacaine and dexamethasone were measured for 96 h. The onset time was reduced and the duration of analgesia increased over the 0.3125%-5.0% dose range (P Ͻ 0.02). Onset with 2.5% microcapsules approximated that of 0.25% aqueous bupivacaine. Microcapsule block duration increased to at least 96 h and was significantly longer than aqueous bupivacaine (P Ͻ 0.001). Inclusion of dexamethasone increased the duration of pinprick anesthesia in 2.5% microcapsules (P ϭ 0.03). We conclude that bupivacaine/dexamethasone microcapsules are well tolerated and demonstrate a dose-related effect in onset and duration of intercostal blockade. Inclusion of dexamethasone increases intercostal block anesthesia. (Anesth Analg 2003;96:576 -82) 
B
iodegradable bupivacaine-containing polymer microcapsules have produced a local anesthetic duration of longer than 7 days in several animal models (1) . Anesthetic duration correlates with the total dose of bupivacaine-containing microcapsules injected in these models. Furthermore, the inclusion of a small amount of dexamethasone (0.04%) within the microcapsules has been demonstrated to further extend the duration (2) . Although intercostal blockade with bupivacaine-containing microcapsules has produced a marked prolongation of intercostal blockade in sheep (3) , no studies have been performed with microcapsules for intercostal nerve blockade in humans.
Intercostal blockade with aqueous local anesthetic produces plasma local anesthetic concentrations that are larger than those observed after all other regional anesthetic techniques (4, 5) . Because the proportion of bupivacaine contained in microcapsules approximates 72% by weight, the milligram amount of bupivacaine injected far exceeds that which is often injected when aqueous solutions are used, so adverse effects due to systemic bupivacaine absorption are a genuine concern.
The objectives of this study were to determine the effect of escalating doses of bupivacaine-containing microcapsules on the onset and duration of intercostal blockade and to assess the influence on these clinical variables of including a small amount of dexamethasone within the microcapsules. Additionally, the pharmacokinetic variables of bupivacaine released from these microcapsules and the immediate and long-term safety of bupivacaine microcapsules when used for intercostal nerve blockade in humans were investigated.
Methods
Thirty-six healthy volunteers of either sex participated after IRB approval and written informed consent were obtained. A history of local anesthetic sensitivity, thoracic trauma or surgery, any concomitant drug therapy, or a history of smoking or asthma were exclusions. Subjects were fasted for 8 h.
The study was conducted in two parts. Part 1 (24 volunteers) was a randomized, escalating, doseresponse study of dexamethasone-containing bupivacaine microcapsules administered as an intercostal block of T9 through T11 (0.3125%-2.5%, 2 mL per nerve, 6 mL total) compared with aqueous 0.25% bupivacaine administered in a blinded fashion to the contralateral intercostal nerves. This portion of the study investigated the clinical anesthesia characteristics and safety of escalating doses of microcapsules and compared these effects with those of aqueous bupivacaine. A final open-labeled group of six volunteers received unilateral block with a larger concentration (5.0%) of dexamethasone-containing microcapsules to further characterize the dose response of the formulation and to evaluate safety at larger doses.
Part 2 of the study, which was randomized and double-blinded, assessed the effect of dexamethasone inclusion within the microcapsule by the unilateral blockade (left, T9 to T11) (6 volunteers) and of microcapsules without dexamethasone (6 volunteers), by using the concentration that consistently produced 3-5 days' effect in Part 1 (2.5%).
Polymer microcapsules (approximately 72% bupivacaine with 0.04% dexamethasone, by weight) were suspended and diluted to produce a final concentration of microcapsules per milliliter (Table 1) . Plasma samples were obtained in all subjects to characterize the pharmacokinetics of bupivacaine and dexamethasone. Each participant received an 18-gauge peripheral IV catheter for infusion of maintenance lactated Ringer's solution and a separate 16-gauge peripheral IV catheter in the contralateral arm for venous blood sampling. No premedication or sedative medications were given.
Intercostal blockade was performed at the angle of the ribs with the volunteer in the prone position. The skin and subcutaneous tissues were anesthetized with 1.0 mL of 0.5% lidocaine (6 mL, 30 mg total) 5 min before initiation of the intercostal nerve blocks. Intercostal blocks were performed by using a flat-bevel 22-gauge needle and standard technique (6), with 6 nerve blocks completed within 4 min. Volunteers evaluated the pain of injection by using an 11-point numeric scale, where 0 ϭ "no pain" and 10 ϭ "pain as bad as you can imagine," immediately after the injections.
One minute after completion of the blocks, subjects were turned supine and remained in this position for 3 h, after which they were allowed to ambulate and resume oral intake. Heart rate and blood pressure were measured at 15-min intervals for 1 h and at all times of clinical assessments thereafter.
Three methods of testing sensory anesthesia and analgesia were used: having each volunteer lightly touch their own abdomen (subjective touch), pinprick (pain), and alcohol wipe (temperature perception). Touch was rated on an 11-point scale: 0 ϭ no numbness and 10 ϭ complete numbness (anesthesia). A numbness score of 5 was arbitrarily defined as "analgesia" on this scale. Pain to pinprick (dental needle) was rated on a three-point scale: 0 ϭ no sensation (anesthesia), 1 ϭ pin sensed as dull pressure (analgesia), and 2 ϭ sharp. Temperature perception was rated on a two-point scale: 0 ϭ alcohol wipe not cold and wet (analgesia) and 1 ϭ cold and wet. Anesthesia and analgesia were tested on the anterior abdomen (midclavicular line, T9 to T11 dermatomes) at baseline; 30 min; 1, 2, 6, 12, and 24 h after injection; and every 24 h thereafter until complete offset of anesthesia. After appropriate training, all subjects additionally performed "self-tests" by using the same methods and recording results in a diary at the 12-h interval between when tested by the trained observer (i.e., 36, 60, and 84 h and so on), and this continued until 14 days after injection. No testing of motor blockade was attempted. Adverse events were assessed through 96 h and again at 2 wk, 6 wk, 2 mo, and 6 mo after injection.
Peripheral venous blood samples (10 mL) for determination of bupivacaine and dexamethasone concentrations were obtained in all subjects at Time 0 (immediately after the last intercostal injection), 15 and 60 min, and 2, 3, 6, 12, 24, 48, 72, and 96 h after the end of intercostal injection. Plasma was immediately separated by centrifugation and stored at Ϫ20°C until assay.
Plasma local anesthetic determinations and pharmacokinetic calculations were performed at Purdue Pharma L.P. (Stamford, CT). Plasma concentrations of bupivacaine were measured by a validated liquid chromatography-mass spectrometry/mass spectrometry method by using multiple reaction mode detection and operating under positive electron spread mode. A stable isotope-labeled bupivacaine was used as internal standard. The peak area bupivacaine/ internal standard ratio was used to construct the calibration curve, with a dynamic range of 5-300 ng/mL. Blank plasma was used to prepare the calibration and quality control samples for the clinical sample analysis. Sample preparation was performed on 96-well solid phase extraction plates, with quality control samples interspersed throughout the analysis.
Plasma concentration-time profiles of bupivacaine and dexamethasone were used to estimate the maximum plasma concentration (C max ), the time to reach C max (t max ), and the area under the plasma concentration-time curve up to the last quantifiable concentration (AUCt, linear trapezoidal rule). The terminal elimination half-lives were not reported because they could not be estimated accurately for all the dose groups.
Continuous data are expressed as mean Ϯ sd. The pharmacokinetic data are presented as mean Ϯ se. Onset and duration of blockade, pain on injection, and maximum degree of numbness were analyzed with analysis of variance (Part 1) with post hoc paired comparisons using Fisher's protected least significant difference tests, unpaired Student's t-tests (Part 2), or repeated-measures analysis of variance. Dose-response effects were evaluated with linear regression analysis. A P value of Ͻ0.05 was chosen as significant.
Results
All volunteers (17 men and 19 women; age, 33 Ϯ 7 yr; weight, 72 Ϯ 13 kg; height, 172 Ϯ 11 cm) completed the study, and no major adverse events occurred. No important hemodynamic alterations were recorded during the study. No symptoms attributable to large systemic concentrations of bupivacaine were observed.
The injection of 0.3125% microcapsules did not produce a discernible block in 2 of the 3 volunteers, and the duration of anesthesia and analgesia was comparable to 0.25% aqueous bupivacaine in the other subject. Therefore, 0.3125% was believed to be the "no effect" concentration. Block was also not discernible in one subject receiving 0.625% microcapsules, one subject receiving 2.5% microcapsules with dexamethasone (Part 2), and two subjects receiving 2.5% microcapsules without dexamethasone (Part 2). Data from these injections were excluded from analysis. The 22-gauge needle became occluded in 2 of the first 3 subjects during the injection of the 5.0% microcapsules. A 20-gauge needle was used for the remaining 3 subjects. Pain on injection did not differ between groups (P ϭ 0.52; mean, 3. 1 Ϯ 2.1; range, 1-10).
Sensory blockade differed in onset, quality, and duration between the groups in Part 1 (Fig. 1a-f ). Sensory blockade appeared most rapidly with aqueous bupivacaine but, as expected, had the shortest duration of effect for all assessment modalities (Fig. 2, a and b) . The maximum "numbness score" did not differ between the aqueous group and the volunteers receiving microcapsules larger than the 0.3125% concentration (P ϭ 0.14). Onset of anesthesia and analgesia decreased with increasing doses of microcapsules for most of the assessment modalities in Part 1 (Fig. 2a) . Furthermore, duration of anesthesia and analgesia increased with increasing microcapsule concentration (Fig. 2b) . Because there was no statistical difference in onset between 0.5% aqueous bupivacaine and the 2.5% microcapsule concentration, this concentration was chosen for injection in Part 2.
There was no difference in onset of analgesia or anesthesia (Fig. 2a) or maximum "numbness score" between groups in Part 2 (P ϭ 0.54). Although anesthesia and analgesia tended to be of longer duration with the dexamethasone-containing microcapsules, statistical significance was reached only for anesthesia to pinprick (Fig. 2b) .
Derived bupivacaine pharmacokinetic variables are shown in Table 2 . Plasma bupivacaine data must be interpreted with caution, because the sources of bupivacaine were heterogeneous in Part 1, in which subjects received bilateral injections. Because aqueous and bupivacaine microcapsules were injected simultaneously, the plasma bupivacaine concentration curves represent a blend of bupivacaine released from microcapsules and that immediately available from the contralateral aqueous injections. Aqueous bupivacaine is known to rapidly distribute into the systemic circulation and is suspected to constitute much of the early peak (within 1 h of injection; Fig. 3 ). This can be confirmed by comparing the 2.5% microcapsule groups in each part, because volunteers in Part 1 received a simultaneous injection of aqueous bupivacaine on the contralateral side (Fig. 3) , whereas those in Part 2 received no contralateral injection (Fig. 3) . Effectively, each subject in Part 1 had two peaks in their plasma bupivacaine concentration-an early (t max ϭ 15 min) C max due primarily to aqueous bupivacaine injection and a late (t max 6 -24 h) C max due to the contralateral injection of microcapsules. This was further verified by the late peak correlating temporally with the t max of the injections in Part 2, where microcapsules alone were injected (Fig. 3) . Plasma dexamethasone pharmacokinetic metrics for the 5.0% microcapsule treatment were t max ϭ 7 h, C max ϭ 198 pg/mL, and AUCt ϭ 3680 pg/mL. The t max of dexamethasone (7 h) was faster than the t max of bupivacaine (12 h) for the 5.0% microcapsule treatment. The mean dexamethasone C max of 100 pg/mL was observed after the administration of 2.5% microcapsules. Systemic exposure to dexamethasone was below the lower limit of quantification for all other concentrations, which prevented further computation of dexamethasone pharmacokinetic metrics.
There were no significant differences in bupivacaine C max in Part 1. Sequential doubling of the concentration of microcapsules resulted in less than doubling of the plasma C max and in less than doubling of the AUCt. In Part 2, the inclusion of dexamethasone reduced the C max and AUCt of bupivacaine. A similar mean t max was observed for bupivacaine from 2.5% (13.0 h) and 5.0% with dexamethasone (12.3 h) and 2.5% without dexamethasone (15.0 h). The mean C max and AUCt for 2.5% microcapsules containing dexamethasone (101.6 ng/mL and 3073.4 ng · h Ϫ1 · mL Ϫ1 , respectively) were lower than the mean C max and AUCt for 2.5% microcapsules without dexamethasone (164.9 ng/mL and 4583.1 ng · h Ϫ1 · mL Ϫ1 , respectively). The mean C max and AUCt for 5.0% dexamethasonecontaining microcapsules (227.8 ng/mL and 7943.8 ng · h Ϫ1 · mL Ϫ1 , respectively) were slightly more than double the mean C max and AUCt for 2.5% dexamethasone-containing microcapsules.
Adverse effects included local tissue reaction, seen only in subjects receiving 5.0% microcapsules (2 of 6 subjects), and paresthesia or injection-site pain, noted in 5 of 36 subjects (1 of 20, aqueous bupivacaine; 1 of 9, microcapsules with dexamethasone 2.5%; and 2 of 6, microcapsules with dexamethasone 5.0%). One subject receiving 5.0% microcapsules had intermittent local paresthesia continue for 3 mo, but this resolved completely by 6 mo after injection. All adverse effects were self-limited, and no treatment was required.
Discussion
This study was designed to evaluate the use of bupivacaine-containing microcapsules for intercostal block in volunteers. Establishing a dose that produces 3-5 days of intercostal blockade would be useful in the treatment of postoperative pain. Our preliminary results in a small number of volunteers confirm that the 2.5% concentration can attain this goal for block duration and that microcapsules containing this concentration of bupivacaine can be used safely for intercostal blockade.
Our results are comparable to those previously reported for intercostal blockade in sheep (3). We found the minimal effective dose for producing analgesia in humans to be 0.625% (2 mL per nerve). This injection delivers 9 mg of bupivacaine base near each nerve. Although the minimal effective dose in sheep initially appears to be much larger (8 mg/kg ϭ approximately 37 mg of bupivacaine per nerve), blockade in these animals was defined as "complete blockade," which would be analogous to anesthesia in this study. Reliable anesthesia was not attained in this study until the 2.5% concentration (36 mg of bupivacaine base per nerve) was used. At the 2.5% concentration, we found the duration of complete anesthesia to be 24 hours, whereas the duration persisted for 5 days in the sheep.
Drager et al. (3) also demonstrated a marked increase in duration of blockade when a small amount of dexamethasone was incorporated into microcapsules. We were also able to demonstrate a prolongation in anesthesia to pinprick by the dexamethasone-containing bupivacaine microcapsules in humans. Although the differences between microcapsules with and without dexamethasone for many of the other anesthesia/analgesia assessments did not reach statistical significance, the tendency for a longer duration with the inclusion of dexamethasone was consistent. Several other differences in methodology (five nerves per side blocked in sheep, three nerves per side blocked in volunteers; injection needle; modifications in microcapsule formulation, and so on) may also contribute to these differences in results.
Different pharmacokinetic mechanisms are in effect for the aqueous and microcapsule preparations. The aqueous preparation is delivered as a bolus, which is followed exclusively by elimination from the site. The amount of bupivacaine delivered into the intercostal space from microcapsules is also initially substantial, as evidenced by the early rapid Figure 2 . a, Onset of intercostal analgesia (pin ϭ 1, not cold, numbness Ͼ5) and anesthesia (pin ϭ 0, maximum numbness) was fastest with the 0.25% aqueous bupivacaine control but was not statistically different from 2.5% microcapsules. No difference in onset was detected between 2.5% microcapsules with or without co-inclusion of dexamethasone. b, Duration of intercostal analgesia and anesthesia was significantly longer for all concentrations of microcapsules Ͼ0.312% compared with the 0.25% aqueous bupivacaine control. Duration of pinprick anesthesia was greater with 2.5% microcapsules containing dexamethasone than with 2.5% microcapsules without dexamethasone.
increase of the drug in the plasma seen in Part 2 (2.5% injections; Fig. 3 ) and for the 5.0% injections (Fig. 3) . This initial peak in plasma bupivacaine is due to the small amount of free drug that exists in solution after suspension of the microcapsules in the diluent. In contrast to the aqueous injection, as elimination of this initial amount begins, additional bupivacaine is delivered to the intercostal space from the injected microcapsules. For the first 12 to 24 hours, the release of additional bupivacaine from the microcapsules exceeds elimination, and the bupivacaine concentration continually increases (Fig.  3) . Beyond that, elimination exceeds further release of bupivacaine, and the plasma bupivacaine concentration declines.
Despite injecting nearly a 10-fold larger total amount of bupivacaine base with the 2.5% microcapsules (Part 2), peak plasma bupivacaine concentrations were comparable to those from the 0.25% aqueous bupivacaine (early peaks in Part 1) . At the dose levels tested, the average peak plasma concentrations (C max ) were well below what are believed to be toxic levels in humans (4 g/mL). If one extrapolates from the plasma levels measured in this study, a volume of 2.5% microcapsules equal to that of 0.25% aqueous solution could be safely used for intercostal block.
Although interpretation of the plasma levels found in Part 1 of this study is limited by the fact that bupivacaine is being absorbed from both the aqueous and the microcapsule sites, this may closely mimic what eventually could occur in the clinical situation. Aqueous local anesthetic solutions produce a reliably rapid onset of blockade. Aqueous local anesthetic may be mixed with microcapsules to attain the combined advantages of rapid onset from the aqueous portion and a marked prolongation of effect from the microcapsules. Such a combined injection would produce plasma levels analogous to those found in Part 1.
It is not possible to determine whether the most common adverse effects seen in this study (injection site reaction and pain) are due to needle trauma, bupivacaine, the polymer microcapsule matrix, or their combination. An induration response to implantable polysaccharide material is well documented and is described as a normal foreign body reaction that occurs with biodegradation (7). This self-limited foreign body reaction is often associated with pruritus and can persist for the lifetime of the microcapsules. This reaction can develop regardless of whether or not the microcapsules are actually carrying any active drug, has been observed after the subcutaneous injection of bupivacaine-loaded microcapsules, and typically occurs much later than the peak plasma concentrations of the drug it is carrying. Neither induration nor pruritus was observed in this study.
Blockade of a limited number of intercostal nerves remains a valuable model for the study of local anesthetics in humans. The anatomy of the intercostal nerve in relation to its overriding rib is predictable and provides for a reliable and reproducible block. Our study is limited by the inability to measure motor blockade. Because there is overlap between sequential intercostal nerves, a minimum of three nerves must be blocked to consistently produce a "band" of sensory anesthesia. We chose to block three nerves per side in this study to minimize the exposure of subjects to the investigational drug. Motor blockade can be reliably measured after intercostal block (6), but because six or seven nerves provide innervation to the abdominal musculature, more blocks must be performed. In conclusion, the intercostal injection of dexamethasone-containing bupivacaine microcapsules produces a prolonged duration of anesthesia and analgesia. Onset of intercostal blockade is inversely related to microcapsule concentration from 0.3125%-2.5%, and less than 2.5% onset is slower than that produced by aqueous bupivacaine (0.25%). Inclusion of dexamethasone within microcapsules produces a prolongation in anesthesia to pinprick. The duration of intercostal block is directly related to dose/concentration, and anesthesia or analgesia lasting up to 96 h can be produced. Figure 3 . a, Time course of mean plasma bupivacaine concentrations obtained over the 96-h study period after bilateral intercostal injection of 0.25% aqueous (6 mL; one side) and 0.312%-2.5% microcapsule bupivacaine (6 mL; second side). The 5.0% microcapsule injections (6 mL) were unilateral. b, Time course of mean plasma bupivacaine concentration obtained over the 96-h study period after unilateral injection of 2.5% microcapsule bupivacaine with or without co-inclusion of dexamethasone. Concentrations are expressed as nanograms per milliliter.
